Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.
The announcement additionally noted that throughout 14 months of follow-up, UP421 maintained its pancreatic islet cell ...
The Hunter syndrome space suffered a setback in February when the FDA turned down REGENXBIO's investigational gene therapy, ...
Health Secretary Robert F. Kennedy Jr. has become increasingly unpopular among several government officials, largely as a result of his antivaccine rhetoric and actions. Other contentious issues ...
With Ascendis Pharma entering the achondroplasia space last month and BridgeBio on deck, BioMarin faces competition. Adding to the pressure, the company suffered a setback Monday when it halted two ...
As the Formula 1 season kicks off in the APAC region, biopharma companies can take a page from the popular sport’s playbook around precision, adaptability, and the right team. In return, biopharma can ...
Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality ...
Dozens of biotechs reported earnings this week. BioSpace recaps key highlights from Capricor Therapeutics, Legend Biotech, ...
Breakout Ventures’ focus on early-stage companies stands out as more and more investors elect to save their dollars for ...
Single-trial approvals are raising the bar on trial design and execution. The new paradigm is pushing sponsors to plan ...
In this episode of Denatured, you'll listen to Oxana Iliach, senior director of regulatory strategy at Certara and Vera ...
Among the unreported adverse events potentially linked to Ozempic are two deaths and one case of “completed suicide,” according to an FDA inspection report.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results